The FDA’s 2025 updated real-world evidence (RWE) guidance reflects a shift from exploration to expectation. Rather than asking whether RWE can support regulatory decisions, the focus is now on how well it does. This distinction raises the bar for sponsors, CROs, and IRB oversight, making it clear that real-world data must be supported by rigorous design, transparent methods, and clear justification from the start.
This article, featured in Clinical Leader, reviews:
- What has changed in the FDA real-world evidence guidance, including stronger expectations around data relevance, reliability, and documentation
- Why study design and transparency are now central to demonstrating that RWE is fit for regulatory use
- What sponsors, CROs, and IRBs should do to take advantage of RWE as a first-class evidentiary pathway
Read the full piece for essential details and next steps.
